The utilization of glutathione peroxidase 4 (GPX4, one of the core regulatory factors of ferroptosis174) inhibitors can effectively attenuate tumor proliferation and enhance antitumor immunity, while combining GPX4 inhibitors with immunotherapy can further impede tumor progression.175 Furthermore, in breast cancer, tumors exhibiting high levels of imaging tumor heterogeneity are associated with a poor prognosis. This evidence concerns the gene GPX4 and breast cancer.